Advertisement

Topics

AstraZeneca gets FDA nod for Fasenra to treat severe eosinophilic asthma

05:30 EST 15 Nov 2017 | Pharmaceutical Business Review

AstraZeneca, along with its wholly owned subsidiary MedImmune, has secured approval from the US Food and Drug Administration (FDA) for Fasenra (benralizumab) for the treatment of severe eosinophilic asthma.

Original Article: AstraZeneca gets FDA nod for Fasenra to treat severe eosinophilic asthma

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca gets FDA nod for Fasenra to treat severe eosinophilic asthma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...